UBS lowered the firm’s price target on Inspire Medical to $322 from $405 and keeps a Buy rating on the shares. Current multiples seem to be pricing in an overly bearish view, in which TAMs are cut meaningfully as GLP-1 adoption ramps, specifically in diabetes and obstructive sleep apnea, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INSP:
- 3 Best Stocks to Buy Now, 8/25/2023, According to Top Analysts
- Inspire Medical price target lowered to $340 from $363 at Truist
- Inspire Medical Systems, Inc. to Present at the Wells Fargo 2023 Healthcare Conference
- Inspire Medical price target raised to $330 from $315 at Wells Fargo
- Inspire Medical price target raised to $350 from $305 at Lake Street